Flag of the European Union EU Clinical Trials Register Help

Clinical trials for eli lilly

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,061 result(s) found for: eli lilly. Displaying page 3 of 54.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-004675-52 Sponsor Protocol Number: I4V-MC-JAHA Start Date*: 2017-07-11
    Sponsor Name:Eli Lilly and Company
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24 Week Study Followed by Long-Term Treatment for Evaluation of Efficacy and Safety of Baricitinib in Patients with Active Psoriatic Art...
    Medical condition: Active Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) ES (Prematurely Ended) HU (Completed) PL (Prematurely Ended) IT (Completed) RO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-003490-33 Sponsor Protocol Number: H9X-MC-GBGL Start Date*: 2018-04-23
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients with Type 2 Diabetes Mellitus
    Medical condition: Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) GR (Completed) AT (Completed) HU (Completed) PL (Completed) ES (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2018-004614-18 Sponsor Protocol Number: I6T-MC-AMAM Start Date*: 2019-07-10
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Acti...
    Medical condition: moderately to severely active Crohn’s disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed) FR (Completed) GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed) ES (Completed) PL (Completed) DK (Completed) BE (Completed) SK (Completed) LT (Completed) CZ (Completed) LV (Completed) HR (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2010-018759-82 Sponsor Protocol Number: F3Z-EW-IOPT Start Date*: 2010-06-16
    Sponsor Name:Eli Lilly and Company
    Full Title: The Effect of Postprandial Hyperglycemia on Arterial Stiffness in Patients with Type 2 Diabetes
    Medical condition: Type 2 diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2016-003331-38 Sponsor Protocol Number: I1F-MC-RHCD Start Date*: Information not available in EudraCT
    Sponsor Name:Eli Lilly and Company
    Full Title: Multicenter, Double-Blind, Randomized, Active- and Placebo Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients from 6 to Less than 18 Years of Age with Moderat...
    Medical condition: Moderate-to-Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) ES (Completed) PL (Completed) HU (Completed) CZ (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-003791-23 Sponsor Protocol Number: I4T-MC-JVDB Start Date*: 2015-04-23
    Sponsor Name:Eli Lilly and Company
    Full Title: Protocol I4T-MC-JVDB Randomized Phase 2 Trial Evaluating Pharmacokinetics and Safety of Four Ramucirumab Dosing Regimens in Second Line Gastric or Gastroesophageal Junction Adenocarcinoma
    Medical condition: Second Line Gastric or Gastroesophageal Junction Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063916 Metastatic gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) FR (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2004-002537-39 Sponsor Protocol Number: H3E-IT-S079 Start Date*: 2005-04-04
    Sponsor Name:ELI LILLY
    Full Title: Phase II Trial of Neoadjuvant ALIMTA plus Cisplatin followed by Surgery and Radiation in the Treatment of Pleural Mesothelioma
    Medical condition: Plaural Mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000225-51 Sponsor Protocol Number: ITP-NODAT Start Date*: 2012-11-21
    Sponsor Name:Fundació Institut Mar d'investigacions Mediques
    Full Title: Insulin Therapy for the Prevention of New Onset Diabetes after Transplantation (ITP-NODAT) Prospective Study in Non-Diabetic De Novo Kidney Transplant Recipients
    Medical condition: Previously non-diabetic end stage renal disease patients undergoing kidney transplantation.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012713-22 Sponsor Protocol Number: version 28.10.2009 Start Date*: 2010-05-06
    Sponsor Name:Medizinische Universität Wien, Univ. Klinik für Anästhesie, Allg. Intensivmedizin u Schmerztherapie
    Full Title: Randomized Double-blind Study Comparing the Efficacy of Duloxetine with Placebo in Patients with Chronic Low Back Pain
    Medical condition: efficacy of duloxetine in the treatment of patients with chronic low back pain to placebo
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003424-31 Sponsor Protocol Number: I4V-MC-JAGA Start Date*: Information not available in EudraCT
    Sponsor Name:Eli Lilly and Company
    Full Title: Treatment of Conditions Expected to Benefit from JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, SAVI, and Severe Juvenile Dermatomyositis
    Medical condition: CANDLE, CANDLE-Related Conditions, SAVI, and Severe Juvenile Dermatomyositis, Aicardi-Goutieres Syndrome
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-002495-13 Sponsor Protocol Number: J1B-MC-FRCF Start Date*: 2020-04-20
    Sponsor Name:Eli Lilly & Company
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Crossover Study to Evaluate the Efficacy and Safety of LY3454738 in Adults with Chronic Spontaneous Urticaria Inadequately Contr...
    Medical condition: Chronic Spontaneous Urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001194-25 Sponsor Protocol Number: H6D-MC-LVJJ Start Date*: 2013-09-25
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Tadalafil for Duchenne Muscular Dystrophy
    Medical condition: Duchenne Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (Prematurely Ended) IT (Prematurely Ended) DE (Completed) ES (Prematurely Ended) BE (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004585-25 Sponsor Protocol Number: I1F-MC-RHCF Start Date*: 2017-05-26
    Sponsor Name:Eli Lilly and Company
    Full Title: A 52-Week Multicenter, Randomized, Open-Label, Parallel-Group Study Evaluating the Efficacy and Safety of Ixekizumab versus Adalimumab in Patients with Psoriatic Arthritis Who Are Biologic Disease-...
    Medical condition: Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000018188 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FI (Completed) DE (Completed) NL (Completed) BE (Completed) AT (Completed) SE (Completed) DK (Completed) ES (Completed) GB (Completed) FR (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-004092-31 Sponsor Protocol Number: I6T-MC-AMAP Start Date*: 2018-06-25
    Sponsor Name:Eli Lilly and Company
    Full Title: I6T-MC-AMAP A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long- Term Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis (LU...
    Medical condition: moderately to severely active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) LT (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) DK (Trial now transitioned) LV (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) DE (Completed) ES (Ongoing) AT (Trial now transitioned) SK (Trial now transitioned) HR (Prematurely Ended) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003339-53 Sponsor Protocol Number: I8H-MC-BDCL Start Date*: 2020-09-22
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2, Parallel, Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-004243-23 Sponsor Protocol Number: J1S-MS-JV02 Start Date*: 2021-05-10
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Open-Label Phase 2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with relapsed, Recurrent, or Refractory Synovial Sarcoma.
    Medical condition: Synovial Sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042863 Synovial sarcoma PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) BE (Completed) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004242-42 Sponsor Protocol Number: J1S-MC-JV01 Start Date*: 2021-05-12
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Open-Label Phase 2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor.
    Medical condition: Desmoplastic small round cell tumour (DSRCT)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064581 Desmoplastic small round cell tumour PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Ongoing) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000079-35 Sponsor Protocol Number: J2J-OX-JZLC Start Date*: 2021-11-02
    Sponsor Name:Eli Lilly and Company
    Full Title: EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive, HER2 Neg...
    Medical condition: Breast Neoplasms, Neoplasm Metastasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) DE (Ongoing) CZ (Completed) FR (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004737-33 Sponsor Protocol Number: 5706 Start Date*: 2018-05-16
    Sponsor Name:Hôpitaux Universitaires de Strasbourg
    Full Title: A prospective, multicenter, randomized, open-label study of 12 week duration to evaluate the effect of VILDagliptin added to insulin on glycaemic control in haemoDIALyzed patients with type 2 diabe...
    Medical condition: haemodialyzed patients with type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004861 10049746 Insulin-requiring type II diabetes mellitus LLT
    18.0 100000004865 10018874 Haemodialysed LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003365-34 Sponsor Protocol Number: I4V-MC-JAIV Start Date*: 2019-05-02
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Primary Biliary Cholangitis Who Have an Inadeq...
    Medical condition: Primary Biliary Cholangitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10008604 Cholangitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Apr 22 17:18:34 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA